Cellbox Labs
Cellbox Labs is a Riga-based deep-tech company (founded 2020) that develops and sells industrialized organ-on-chip platforms — mass-manufactured COC chips, automated cultivation instruments, and contract research services — to pharmaceutical, biotechnology, and academic customers for drug testing, disease modeling, and toxicology.
- Company typePrivate
- Founded2020
- HeadquartersRiga, Latvia
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cellbox Labs does
Cellbox Labs is a Latvian deep-tech startup headquartered in Riga that develops and commercializes industrial organ-on-chip (OoC) technology for pharmaceutical, biotechnology, and academic customers. Founded in 2020 by Gatis Mozolevskis (CEO), Roberts Rimsa (CTO), and Arturs Abols (CSO), the company has built a team of approximately 17 PhD-level researchers, engineers, and project managers bridging microfluidics, cell biology, and precision manufacturing.
The company's core offering is a vertically integrated platform comprising three components: (1) the Dynamic Organ Chip — a mass-manufacturable, PDMS-free COC (cyclic olefin copolymer) chip with stacked endothelial/epithelial channels and a permeable membrane supporting up to four organs per chip; (2) the Automated System — an instrument with a modular manifold (8 to 24 chips), proprietary pumping, integrated bright-field microscopy for real-time monitoring, embedded software for remote experiment design, and controlled gas environments for hypoxia modeling; and (3) Contract Research Services — tailored experimental protocols, feasibility studies, and model development for intestinal, cancer, vasculature, and microbiome applications using primary cells, iPSCs, and patient-derived organoids. A BSL3-compatible cultivation system has been filed for patent.
Cellbox Labs monetizes through direct enterprise sales of hardware (chips and instruments) priced via custom quotation, alongside contract research services. Revenue is supplemented — but not principally driven — by EU non-dilutive grant funding through programs including IPCEI (€3.3M, 2025), Eurostars, and ERDF. The go-to-market motion is enterprise field sales activated through scientific conference presence (MPS World Summit, SLAS, EUROoCS, WORD+, CSEM) and a website-driven "Get a Quote" funnel, with no channel partner or reseller distribution. As of mid-2025 the company is operating with roughly €4.2M cumulative funding, one patent pending, and recognition including the Latvian Startup Award (IMPACT, 2024) and EIT Health Catapult semi-finalist status.
Cellbox Labs firmographics
Firmographics- Name
- Cellbox Labs
- Legal name
- Cellboxlabs SIA
- Website
- https://cellboxlabs.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Cellbox Labs is a Riga-based deep-tech company (founded 2020) that develops and sells industrialized organ-on-chip platforms — mass-manufactured COC chips, automated cultivation instruments, and contract research services — to pharmaceutical, biotechnology, and academic customers for drug testing, disease modeling, and toxicology.
- Ownership category
- akta.pro rank
Cellbox Labs industry classification
Industry- Product category
- Organ-on-chip instruments and consumables
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826), Laboratory Apparatus & Furniture (3821)
- akta.pro primary industry
- Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD)
- akta.pro secondary industry
- Cell Culture & Bioprocess Lab Equipment (Bioreactors, Single-Use Systems, Controllers) (HLAGAIAG)
Keywords
Where Cellbox Labs is headquartered
LocationHeadquarters
- HQ city
- Riga
- HQ country
- Latvia
- HQ region
- Europe
Offices1 record
Markets served
Cellbox Labs business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Organ-on-Chip Hardware Products: Sale of mass-manufactured COC chip devices and automated cultivation instruments (Dynamic Organ Chip, Automated System with manifold). Products are sold directly to pharmaceutical, biotech, and academic customers for drug testing, disease modeling, and research applications.
- Contract Research Services: Tailored experimental protocols and feasibility studies performed by Cellbox Labs scientific team. Services cover in vitro pharmacology (PK/PD studies, toxicity and efficacy testing), host-microbiota interaction studies, biological barrier transport and integrity testing, and disease modeling. Uses primary cells, cancer cell lines, patient-derived cells, iPS-derived cells, and co-cultures.
- EU Research Grants and Project Funding: Company participates in multiple EU-funded research projects (IPCEI, Eurostars, ERDF,Competence Centre) that provide project-based funding for technology development and validation. This supports R&D but represents non-dilutive funding rather than commercial revenue.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom Quote-Based Pricing |
Go-to-market motion3 records
Distribution channels1 record
Marketing channels6 records
Cellbox Labs product offering
Product offeringCore offering
Cellbox Labs designs, mass-manufactures, and sells an integrated industrial organ-on-chip platform consisting of mass-produced COC chip devices and an automated cultivation instrument with integrated real-time microscopy, software, and proprietary pumping and gas-control systems. The company also delivers tailored contract research services covering in vitro pharmacology, disease modeling, and feasibility studies using primary cells, iPSC-derived cells, organoids, and co-cultures for pharmaceutical, biotech, and academic customers.
Product overview
Cellbox Labs offers an industrial organ-on-chip platform consisting of three integrated components: the Dynamic Organ Chip (mass-manufacturable chips with vertically stacked channel design), the Automated System (instrument with modular manifold expandable from 8 to 24 chips), and Contract Research Services. The platform combines microfluidics with living cells to recreate tissue-specific microenvironments for drug testing, cancer research, and toxicology applications. All components are designed to work together as a unified system with integrated real-time microscopy and software control.
Differentiator
Problem solved
Functional benefit
Products and services
- Dynamic Organ Chip A mass-manufactured, dynamic organ-on-chip device with a vertically stacked channel design that separates endothelial and epithelial channels via a permeable membrane. Made from COC (cyclic olefin copolymer) instead of PDMS, the chips are single-use and EtO-sterilized, with selectable membrane pore sizes and porosities. Supports integration of up to four organs on a single chip and is sold to pharmaceutical, biotech, and academic customers for drug testing, disease modeling, and toxicology applications.
- Automated System An automated cultivation instrument with a modular manifold expandable from 8 to 24 chips, providing controlled flow, gas environment, and integrated bright-field microscopy for real-time monitoring. The system includes embedded software for flexible experiment design, automatic full-channel image capture in approximately 2 minutes, and remote monitoring from office or home. Designed for user-friendly operation with a target of a few hours of training and no prior microfluidics experience required, and is sold to pharmaceutical, biotech, and academic customers.
- Contract Research Services Tailored experimental protocols, feasibility studies, optimization, and proof-of-concept testing performed by the Cellbox Labs scientific team, using the company's organ-on-chip platform with established intestinal, cancer, and vasculature models. Services cover in vitro pharmacology including PK/PD studies, toxicity and efficacy testing, host-microbiota interaction studies, biological barrier transport and integrity testing, and disease modeling, using primary cells, cancer cell lines, patient-derived cells, iPS-derived cells, and co-cultures. Sold to pharmaceutical, biotech, and academic customers.
Quantifiable outcome
- Automated system captures images of entire channel in just 2 minutes
- +4 more outcomes
Companies that use Cellbox Labs
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Cellbox Labs technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature7 records
Cellbox Labs partnerships and signals
Strategic signalPartnerships
16 partnerships are on record, tiered minor and core.
- PHARMIDEAminorPHARMIDEA is the cooperation partner in the COMPETE project (Project No. 1.1.1.3/1./24/A/157), focused on comparing organ-on-chip versus traditional systems for Ozempic generic quality assessment. Project period June 2025 to May 2027, costs €873,448.
- BMC (Biomedical Research & Study Centre)minorBMC is the Principal Investigator host institution for the DIGI-MET2D project (Project No. 1.1.1.3/1./24/A/043, costs €656,455), with Dr. Ilze Elbere as PI. Project focuses on precision metformin dosing using digital twin and gut-on-a-chip models for Type 2 Diabetes patients.
- ESQlabsminorESQlabs was contracted under the DIGI-MET2D project for digital twin model development, as part of the project's approach to integrating digital twin simulations with organ-on-chip technology for personalized Type 2 Diabetes treatment.
- Institute of Solid State Physics, University of LatviaminorListed as cooperation partner in the MIRACLE project (Project No. 1.1.1.3/1./24/A/156, €855,505, May 2025–April 2027), focused on real-time multi-modal monitoring platform for organ-on-chip models integrating optical sensors and impedance spectroscopy.
- Dr. Maira Elksne Research GroupminorLed by Dr. Maira Elksne, this collaboration in the Real-time electrochemical detection project (Project No. 1.1.1.3/1./24/A/052, €677,328, May 2025–April 2028) aims to develop electrochemical sensor technology for continuous ATP and glucose monitoring in organ-on-chip systems.
- KTH Royal Institute of TechnologyminorKTH Royal Institute of Technology is a project partner in the GBA-Connect project (Eureka Eurostars 5304, period April 2024–March 2026, €250,000), alongside Latvian Biomedical Research & Study Centre, Teadusmosaiik OÜ, and Fewer Moving Parts Ltd. Focus on vascularized Gut-Brain-Axis-on-chip platform.
- Teadusmosaiik OÜminorListed as a partner in the GBA-Connect Eurostars project (project No. 5304, €250,000, April 2024–March 2026).
- Fewer Moving Parts LtdminorListed as a partner in the GBA-Connect Eurostars project (project No. 5304, €250,000, April 2024–March 2026).
- Leibniz InstituteminorListed as a partner on the Cellbox Labs website's 'Our Partners' section. The partnership involves advancing frontiers of scientific discovery in cell research.
- Altis BiosystemscoreListed as a partner on the Cellbox Labs website. Altis Biosystems is referenced in the VALIDATE project as the source of high-quality primary small intestinal cells for the industrial-grade Gut-on-a-Chip platform. Also listed as a company logo partner on the Cellbox Labs website.
- KTH Royal Institute of TechnologyminorListed as a partner on the Cellbox Labs website. KTH is also a project partner in GBA-Connect (Eureka Eurostars project 5304), collaborating on the vascularized Gut-Brain-Axis-on-chip platform.
- Embion Technologies SAminorListed as a partner on the Cellbox Labs website. Embion is the project coordinator of the HARMONIS Eurostars project (6525), focused on microbiome optimization and nutrition for healthy ageing.
- BMC (Biomedical Research Centre)minorListed as a partner on the Cellbox Labs website. BMC (Latvian Biomedical Research & Study Centre) is a key collaborator in multiple EU projects including LoCBox, PERFORM-CHIP, PROCEX, COMPETE, VALIDATE, DIGI-MET2D, and GBA-Connect.
- CFIminorListed as a partner on the Cellbox Labs website 'Our Partners' section.
- LU (University of Latvia)minorListed as a partner on the Cellbox Labs website. University of Latvia's Institute of Solid State Physics is a project partner in the MIRACLE project and LoCBox project.
- Max Delbrück Center for Molecular MedicineminorListed as a partner on the Cellbox Labs website 'Our Partners' section.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Cellbox Labs competitors and assessment
Company assessmentDirect peers
- Emulate: Emulate is the leading commercial organ-on-chip company, offering the Emulate Chip-A1 and associated instruments. Direct competitor in the same OoC product category targeting pharma and biotech customers; significantly larger and more commercially mature.
- MIMETAS: MIMETAS provides organ-on-chip platforms (OrganoPlate) for compound screening and disease modeling, with a strong focus on high-throughput applications. Directly comparable product offering for pharma and biotech preclinical researchers.
- CN Bio: CN Bio offers PhysioMimix organ-on-chip systems for drug discovery and disease modeling, including liver, lung, and gut models. Comparable hardware-plus-consumables OoC platform serving pharma R&D customers.
- TissUse: TissUse develops multi-organ-chip (MOC) platforms enabling interconnection of multiple organ models. Comparable OoC technology targeting drug testing and ADME applications.
- Hesperos: Hesperos produces human-on-a-chip multi-organ systems for toxicity and efficacy testing, particularly serving orphan disease and rare disease drug development. Comparable OoC service-and-platform model.
- SynVivo: SynVivo offers microfluidic organ-on-chip platforms for drug delivery and toxicity studies, including tumor and BBB models. Comparable product offering and customer base in pharma and academic research.
Emerging players
- InSphero: InSphero provides 3D cell culture models and organoids for drug discovery, with overlap in disease modeling and toxicology. Comparable target customer base, though focuses on static 3D models rather than microfluidic OoC platforms.
- Bi/ond: Bi/ond develops organ-on-chip platforms with focus on scalable and reproducible in vitro models for pharma applications. Comparable emerging European OoC start-up with overlapping customer focus.
Broad incumbents
- Organovo: Organovo is an early pioneer in 3D bioprinted human tissue for preclinical research and therapeutic applications. Broader incumbent in tissue engineering space with adjacent but different technology approach.
Others
- Altis Biosystems: Altis Biosystems provides primary intestinal epithelial cell models and is a named partner of Cellbox Labs on the VALIDATE project. Adjacent ecosystem participant supplying biological inputs for Cellbox's gut-on-chip platform.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Cellbox Labs social profiles
Digital presenceCellbox Labs financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cellbox Labs leadership team
Management profileNumber of profiles
Profiles14 records
Cellbox Labs funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cellbox Labs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cellbox Labs
What does Cellbox Labs do?
Cellbox Labs designs, mass-manufactures, and sells an integrated industrial organ-on-chip platform consisting of mass-produced COC chip devices and an automated cultivation instrument with integrated real-time microscopy, software, and proprietary pumping and gas-control systems. The company also delivers tailored contract research services covering in vitro pharmacology, disease modeling, and feasibility studies using primary cells, iPSC-derived cells, organoids, and co-cultures for pharmaceutical, biotech, and academic customers.
Is Cellbox Labs a public or private company?
Cellbox Labs is a private company. It is classified as venture growth investor backed and is currently operating.
When was Cellbox Labs founded?
Cellbox Labs was founded in 2020. It employs 1 to 10 people.
Where is Cellbox Labs based?
Cellbox Labs is headquartered in Riga, Latvia, in the Europe region.
How does Cellbox Labs make money?
Three revenue lines are on record. Organ-on-Chip Hardware Products are the primary driver. The others are contract Research Services and EU Research Grants and Project Funding.
Who are Cellbox Labs's main competitors?
Direct peers on record are Emulate, MIMETAS, CN Bio, TissUse, Hesperos and SynVivo. Emerging players are InSphero and Bi/ond. Organovo is listed as a broad incumbent. Altis Biosystems is listed as an others.
Does Cellbox Labs have an API?
No public API is recorded for Cellbox Labs.
What industry is Cellbox Labs in?
Cellbox Labs's product category is Organ-on-chip instruments and consumables. Its primary akta.pro industry code is HLAAAGAD, Organoids & Organ-on-Chip (regenerative models), with a secondary code of HLAGAIAG, Cell Culture & Bioprocess Lab Equipment (Bioreactors, Single-Use Systems, Controllers). Its NAICS code is 334516 and its SIC code is 3841.